Cargando…
Application of Proteomics to Soft Tissue Sarcomas
Soft tissue sarcomas are rare and account for less than 1% of all malignant cancers. Other than development of intensive therapies, the clinical outcome of patients with soft tissue sarcoma remains very poor, particularly when diagnosed at a late stage. Unique mutations have been associated with cer...
Autores principales: | Kondo, Tadashi, Kubota, Daisuke, Kawai, Akira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388341/ https://www.ncbi.nlm.nih.gov/pubmed/22778956 http://dx.doi.org/10.1155/2012/876401 |
Ejemplares similares
-
Discovery of Biomarkers for Osteosarcoma by Proteomics Approaches
por: Suehara, Yoshiyuki, et al.
Publicado: (2012) -
The proteomic landscape of soft tissue sarcomas
por: Burns, Jessica, et al.
Publicado: (2023) -
Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma
por: Kim, Youngji, et al.
Publicado: (2021) -
Proteomic and Metabolomic Profiling in Soft Tissue Sarcomas
por: Chadha, Madhumeeta, et al.
Publicado: (2022) -
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017)